O60674 (JAK2_HUMAN) Homo sapiens (Human)

Tyrosine-protein kinase JAK2 UniProtKBInterProSTRINGInteractive Modelling

1132 aa; Sequence (Fasta)

Available Structures

161 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Structure of human JAK2 FERM/SH2 in complex with Erythropoietin Receptor
6e2q
 Heteromer
P19235; 		36-514
Assess
Structure of human JAK2 FERM/SH2 in complex with Leptin Receptor
6e2p
 Heteromer
P48357; 		38-514
1×SO4;
Assess
Crystal Structure of the E372K LNK SH2 Domain mutant in Complex with a JAK2 pY813 Phosphopeptide
8cz9
 Heteromer
O09039; 		811-818
1×CL;
Assess
Crystal structure of PTP1B D181A/Q262A/C215A phosphatase domain with a JAK2 activation loop phospho…
8eya
 Heteromer
P18031; 		1005-1010
1×TRS; 1×EDO; 3×CL; 2×NA;
Assess
Crystal structure of PTP1B D181A/Q262A/C215A phosphatase domain with monophosphorylated JAK2 activa…
8f88
 Heteromer
P18031; 		1005-1010
2×TRS;
Assess
Crystal structure of PTP1B D181A/Q262A phosphatase domain with JAK2 activation loop phosphopeptide
8exk
 Heteromer
P18031; 		1006-1010
1×PO4;
Assess
Crystal structure of PTP1B D181A/Q262A/C215A phosphatase domain with JAK2 activation loop phosphope…
8eyb
 Heteromer
P18031; 		1005-1009
1×TRS;
Assess
X-ray co-crystal structure of compound 27 in with complex JAK2
8g8x
homo-2-mer842-1130
2×YT8;
Assess
The crystal structure of JAK2 in complex with Compound 31
8g8o
homo-2-mer842-1130
2×YT0; 1×DMS; 1×EDO;
Assess
JAK2 crystal structure in complex with Compound 13
8g6z
homo-2-mer843-1131
2×YSI; 1×EDO;
Assess
Crystal structure of JAK2 JH2-K539L
8c08
homo-2-mer536-810
2×ATP; 2×MG; 1×GOL;
Assess
Crystal Structure of the FERM-SH2 Domains of Jak2
4z32
monomer37-514
Assess
JAK2 kinase (JH1 domain) in complex with compound 9
4jia
monomer833-1132
1×1K3; 1×GOL;
Assess
JAK2 kinase (JH1 domain) in complex with 2,6-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL…
4gmy
monomer833-1132
1×0X5;
Assess
Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that…
5wev
monomer833-1130
1×9ZS;
Assess
JAK2 kinase (JH1 domain) triple mutant in complex with compound 12
4e6q
monomer835-1132
1×0NV;
Assess
JAK2 kinase (JH1 domain) in complex with compound 30
4e4m
monomer835-1132
1×0NH;
Assess
High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to PN5-114.
7ll4
monomer839-1132
1×Y5D;
Assess
Crystal structure of JAK2 JH1 in complex with momelotinib
8bxh
monomer840-1132
1×C87; 1×MLI;
Assess
Crystal structure of JAK2 JH1 in complex with ilginatinib
8bx9
monomer840-1132
1×S59; 1×DMS;
Assess
High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to PN5-150.
7ll5
monomer840-1132
1×EDO; 1×Y5G;
Assess
Crystal structure of JAK2 JH1 in complex with cerdulatinib
8bx6
monomer840-1132
1×S5I;
Assess
Crystal structure of JAK2 JH1 in complex with gandotinib
8bm2
monomer840-1132
1×QQC;
Assess
Crystal structure of JAK2 JH1 in complex with pacritinib
8bpv
monomer840-1132
1×6T3;
Assess
Fragment based discovery of JAK-2 inhibitors
3e64
monomer839-1131
1×5B3;
Assess
Crystal structure of JAK2 JH1 in complex with lestaurtinib
8bpw
monomer840-1132
1×2V9;
Assess
Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors
4d0x
monomer839-1131
1×953; 1×GOL;
Assess
Crystal structure of JAK2 JH1 in complex with itacitinib
8bxc
monomer840-1132
1×S4R;
Assess
Fragment based discovery of JAK-2 inhibitors
3e62
monomer839-1131
1×5B1;
Assess
JAK2 kinase (JH1 domain) triple mutant in complex with compound 7
4e6d
monomer840-1132
1×0NU;
Assess
Structure of Janus kinase 2 with a pyrrolotriazine inhibitor
3q32
monomer840-1132
1×J2I;
Assess
High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to YM2-059
7ree
monomer839-1130
1×4LY;
Assess
JAK2 kinase (JH1 domain) in complex with the inhibitor TRANS-4-[(8AS)-2-[(1R)-1-HYDROXYETHYL]IMIDAZ…
4iva
monomer841-1132
1×1J5;
Assess
High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to type-II inhibitor BBT5…
7rn6
monomer839-1130
1×046; 1×EDO;
Assess
JAK2 in complex with 4-(2-amino-8-methoxyquinazolin-6-yl)phenol
7q7k
monomer840-1131
1×9I5;
Assess
Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors
4d0w
monomer839-1130
1×GOL; 1×VVQ;
Assess
JAK2 in complex with 4-{8-methoxy-2-[(1-methyl-1H-pyrazol-4-yl)amino]quinazolin-6-yl}phenol
7q7i
monomer840-1131
1×9I8;
Assess
Crystal Structure of JAK2 complexed with a potent quinoxaline ATP site inhibitor
3krr
monomer840-1131
1×DQX;
Assess
JAK2 in complex with 4-(2-{[5-(dimethylamino)pentyl]amino}-8-{[(2S)-1-hydroxypropan-2-yl]amino}quin…
7q7w
monomer840-1131
1×9HR;
Assess
Fragment based discovery of JAK-2 inhibitors
3e63
monomer840-1131
1×5B2;
Assess
Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders
5aep
monomer840-1131
1×QUP;
Assess
Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for In…
5tq7
monomer841-1132
1×7GT;
Assess
Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for In…
5tq4
monomer841-1132
1×7GY;
Assess
JAK2 JH1 in complex with JNJ-7706621 (Crystal Form 2)
6drw
monomer840-1131
1×SKE;
Assess
Crystals structure of Jak2 with a 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitor
3rvg
monomer841-1132
1×17P;
Assess
Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for In…
5tq8
monomer841-1131
1×7GS;
Assess
CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-ETHYL-7-[(3-METHOXYPROPYL)…
5cf8
monomer842-1132
1×50V;
Assess
Triazolopyridine-based Inhibitor of Janus Kinase 2
4aqc
monomer842-1132
1×88A; 1×SO4;
Assess
JAK2 JH1 in complex with JNJ-7706621
5usy
monomer840-1130
1×SKE; 2×SO4; 2×GOL;
Assess
JAK2 JH1 in complex with MA9-086
6vnf
monomer841-1131
1×R6S;
Assess
Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for In…
5tq5
monomer841-1131
1×7GX;
Assess
JAK2 kinase (JH1 domain) with 2,6-DICHLORO-N-(2-OXO-2,5-DIHYDROPYRIDIN-4-YL)BENZAMIDE
4gfm
monomer840-1130
1×0X2;
Assess
CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-7-[(DIMETHYL-1,3-THIAZOL-2-YL…
5cf5
monomer842-1132
1×50W;
Assess
JAK2 kinase (JH1 domain) mutant P1057A in complex with TG101209
5hez
monomer842-1132
1×CL; 1×ZN; 2×1M3;
Assess
Human JAK2 JH1 domain in complex with Baricitinib
6wto
monomer843-1132
2×EDO; 1×3JW;
Assess
Human JAK2 JH1 domain in complex with Ruxolitinib
6wtn
monomer843-1132
3×EDO; 1×RXT;
Assess
JAK2 JH1 in complex with PN4-014
6vnj
monomer842-1131
1×R5S;
Assess
Fragment-based discovery of 6-arylindazole JAK inhibitors
5l3a
monomer841-1130
1×6DP;
Assess
Crystal structure of Jak2 complexed with a potent 2,8-diaryl-quinoxaline inhibitor
3lpb
monomer842-1131
1×NVB;
Assess
The structural basis of Janus Kinase 2 inhibition by a potent and specific pan-Janus kinase inhibit…
2b7a
monomer843-1132
1×IZA;
Assess
Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for In…
5tq6
monomer843-1132
1×7GV;
Assess
JAK2 kinase (JH1 domain) in complex with compound 8
4hge
monomer843-1132
1×15V;
Assess
JAK2 kinase (JH1 domain) in complex with TG101209
4ji9
monomer843-1132
1×1M3;
Assess
Discovery and Optimization of C-2 Methyl Imidazo-pyrrolopyridines as Potent and Orally Bioavailable…
4f09
monomer843-1132
1×JAK;
Assess
Crystal structures of JAK1 and JAK2 inhibitor complexes
3fup
monomer843-1132
1×MI1;
Assess
Triazolopyridine compounds as selective JAK1 inhibitors: from hit identification to GLPG0634
4p7e
monomer843-1132
1×2HB;
Assess
Co-crystal structure of jak2 with thienopyridine 8
3tjc
monomer843-1132
1×0TP;
Assess
CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-[(2S)-2,3-DIHYDROXYPROPYL]…
5cf6
monomer842-1131
1×50O;
Assess
Crystal structure of JAK2 kinase domain in complex with compound 30
7uyw
monomer842-1131
1×OV0;
Assess
Structure determination of Aurora Kinase in complex with inhibitor
2w1i
monomer843-1132
1×L0I;
Assess
CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1-CARBOXAMIDE INHIBITOR
4zim
monomer842-1131
1×4OK;
Assess
Design and Synthesis of a pan-JAK kinase inhibitor clinical candidate (PF-06263276) suitable for th…
5tq3
monomer843-1132
1×7GZ;
Assess
Discovery and Optimization of C-2 Methyl Imidazo-pyrrolopyridines as Potent and Orally Bioavailable…
4f08
monomer843-1132
1×1RS;
Assess
co-crystal structure of Jak2 with thienopyridine 19
3tjd
monomer843-1132
1×6TP;
Assess
Crystal structure of JAK2 JH1 with type II inhibitor YLIU-04-105-1
7teu
monomer843-1131
1×I6C; 1×GOL;
Assess
Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors
4d1s
monomer842-1130
1×BJG;
Assess
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the T…
4ytf
monomer842-1130
1×4HZ;
Assess
Crystal Structure of JAK2 in complex with compound 25
6bbv
monomer843-1131
1×D7D;
Assess
JAK2 JH1 in complex with ruxolitinib
6vgl
monomer843-1131
1×RXT;
Assess
JAK2 JH1 in complex with baricitinib
6vn8
monomer843-1131
1×3JW;
Assess
JAK2 in complex with 4-(2-amino-8-{[(2S)-1-hydroxypropan-2-yl]amino}quinazolin-6-yl)-5-ethyl-2-fluo…
7q7l
monomer843-1131
1×9I2; 1×GOL;
Assess
Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity
6tpd
monomer842-1130
1×QZ8;
Assess
JAK2 JH1 in complex with BL2-057
6vs3
monomer843-1131
1×R6V;
Assess
JAK2 JH1 in complex with PN4-073
6vnk
monomer843-1131
1×RXT;
Assess
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the T…
4yth
monomer842-1130
1×467;
Assess
2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2
3iok
monomer842-1130
1×1P6;
Assess
JAK2 JH1 in complex with PN3-115
6vni
monomer843-1131
1×R61;
Assess
Janus Kinase 2 Inhibitors
3jy9
monomer842-1130
1×JZH; 1×NA;
Assess
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the T…
4ytc
monomer842-1130
1×4HW;
Assess
JAK2 JH1 in complex with BL2-084
6vnb
monomer843-1131
1×R6P;
Assess
A Novel Chemotype of Kinase Inhibitors
3kck
monomer842-1130
1×3KC;
Assess
JAK2 JH1 in complex with SY5-103
6vnm
monomer843-1131
1×R5Y;
Assess
JAK2 JH1 in complex with BL2-096
6vnc
monomer843-1131
1×R6V;
Assess
JAK2 JH1 in complex with Fedratinib
6vne
monomer843-1131
1×2TA;
Assess
CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-ETHYL-7-[(3-METHOXYPROPYL)…
5cf4
monomer843-1131
1×50Y;
Assess
JAK2 JH1 in complex with PN2-123
6vnh
monomer843-1131
1×XZS;
Assess
JAK2 JH1 in complex with SG3-179
6vnl
monomer843-1131
1×5W2;
Assess
JAK2 JH1 in complex with PN2-118
6vng
monomer843-1131
1×R6M;
Assess
Human JAK2 JH1 domain in complex with PROTAC-intermediate linker handle 3
6wtp
monomer844-1132
1×U8P; 1×GOL;
Assess
JAK2 JH1 in complex with BL2-110
6vsn
monomer843-1131
1×RG4;
Assess
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the T…
4yti
monomer842-1130
1×VJK;
Assess
2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2
3io7
monomer842-1130
1×1P5;
Assess
Crystal structure of JAK2 with Compound 11
6x8e
monomer843-1130
1×UWP;
Assess
Aminoalkylpyrimidine Inhibitor Complexes with JAK2
4bbe
monomer841-1128
1×3O4;
Assess
Aminoalkylpyrimidine Inhibitor Complexes with JAK2
4bbf
monomer841-1128
1×O19;
Assess
Inhibitors of Jak2 Kinase domain
2xa4
monomer843-1130
1×AZ5;
Assess
Crystal structure of JAK2 in complex with peficitinib
6aaj
monomer843-1130
1×9T6;
Assess
Structural basis of Jak2 inhibition by the type II inhibtor NVP-BBT594
3ugc
monomer843-1129
1×046; 1×MLI;
Assess
Inhibitors of Jak2 Kinase domain
4c61
monomer844-1130
1×LMM; 2×ACT;
Assess
Inhibitors of Jak2 Kinase domain
3zmm
monomer844-1130
1×F9J; 2×ACE;
Assess
Inhibitors of Jak2 Kinase domain
4c62
monomer844-1130
1×XWW; 2×ACT;
Assess
Human JAK2 JH1 domain in complex with PROTAC-intermediate linker handle 4
6wtq
monomer849-1132
1×U8J; 1×TRS; 1×EDO;
Assess
Crystal structure of JAK2 JH2 in complex with Bemcentinib
8ba3
monomer536-812
1×Q8U; 5×GOL;
Assess
Crystal Structure of the E596A V617F Mutant JAK2 Pseudokinase Domain Bound to Mg-ATP
5i4n
monomer537-812
1×ATP; 1×MG; 1×GOL;
Assess
Crystal structure of JAK2 JH2-V617F in complex with Z902-A1
8ba2
monomer536-810
5×GOL; 2×ACT; 1×Q9X;
Assess
JAK2-JH2
7f7w
monomer536-810
1×36H;
Assess
Crystal structure of JAK2 JH2-V617F in complex with HTS-A3
8b8u
monomer536-809
2×GOL; 1×T7I;
Assess
Crystal structure of JAK2 JH2 in complex with Z902-A3
8b9h
monomer536-809
1×Q7F; 4×GOL;
Assess
Crystal structure of JAK2 JH2-V617F in complex with Z902-A3
8b9e
monomer536-809
2×GOL; 1×Q7F;
Assess
Crystal structure of JAK2 JH2-V617F in complex with CB76
8bab
monomer536-809
7×GOL; 1×Q8N;
Assess
Crystal structure of JAK2 JH2-V617F in complex with JNJ-7706621
8b99
monomer536-809
2×GOL; 1×SKE;
Assess
Crystal structure of JAK2 JH2-V617F in complex with Reversine
8bak
monomer536-809
5×GOL; 1×AD5;
Assess
Crystal structure of JAK2 JH2-R683S
8c0a
monomer536-809
1×GOL; 1×T7I;
Assess
Crystal structure of the Jak2 pseudokinase domain (Mg-ATP-bound form)
4fvq
monomer536-809
1×ATP; 1×MG; 2×ACT;
Assess
Crystal structure of the Jak2 pseudokinase domain mutant V617F (Mg-ATP-bound form)
4fvr
monomer536-809
1×ATP; 1×MG;
Assess
Crystal structure of JAK2 JH2-V617F in complex with Cdk2 inhibitor IV
8b8n
monomer536-809
3×GOL; 1×AQG;
Assess
Crystal structure of the Jak2 pseudokinase domain (apo form)
4fvp
monomer536-809
2×GOL;
Assess
JAK2 Pseudokinase in complex with NU6140
5wij
monomer536-809
1×AQG;
Assess
JAK2 JH2 IN COMPLEX WITH JAK292
7t1t
monomer536-809
1×E8I; 1×GOL;
Assess
Crystal structure of JAK2 JH2-V617F in complex with Bemcentinib
8ba4
monomer536-809
1×Q8U;
Assess
JAK2 Pseudokinase in complex with AZD7762
5wil
monomer536-809
1×YDJ;
Assess
JAK2 Pseudokinase in complex with JNJ7706621
5win
monomer536-809
1×SKE;
Assess
JAK2 Pseudokinase in complex with AT9283
5wim
monomer536-809
1×35R;
Assess
JAK2 Pseudokinase in complex with BI-D1870
5wik
monomer536-809
1×584;
Assess
JAK2 JH2 in complex with PRT062607
5ut2
monomer536-808
2×GOL; 1×3YT; 1×ACT;
Assess
JAK2 JH2 in complex with diaminopyrimidine JAK040
6m9h
monomer536-808
1×J9D; 1×GOL; 1×DMS;
Assess
Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with CDK2-IV
8ex0
monomer536-808
1×AQG;
Assess
Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with HTSA3
8ex2
monomer536-808
1×Q2Q; 3×GOL;
Assess
JAK2 JH2 in complex with NVP-BSK805
5ut4
monomer537-809
1×DQX; 2×GOL; 1×DMS;
Assess
JAK2 JH2 IN COMPLEX WITH JAK315
7t0p
monomer536-808
1×E3W; 1×GOL;
Assess
JAK2 Pseudokinase V617F in complex with AT9283
6d2i
monomer536-808
1×35R;
Assess
Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with Reversine
8ex1
monomer537-808
1×AD5; 1×GOL;
Assess
JAK2 JH2 in complex with IKK-2 Inhibitor VI
5ut3
monomer537-808
1×IK1; 3×GOL; 1×ACT;
Assess
JAK2 JH2 in complex with 63552444
6bs0
monomer537-808
1×E4V; 3×GOL;
Assess
Crystal Structure of JAK2-V617F pseudokinase domain in complex with Compound 2
6g3c
monomer537-808
1×EKT; 8×EDO;
Assess
JAK2 JH2 in complex with a diaminopyrimidine
5ut6
monomer537-808
1×8MY; 5×GOL; 1×DMS; 1×ACT;
Assess
JAK2 JH2 in complex with JAK179
6obf
monomer537-808
1×GOL; 1×M4G;
Assess
JAK2 JH2 in complex with JAK020
7jyq
monomer537-808
1×GOL; 1×VPJ;
Assess
Crystal structure of JAK2 JH2-I559F
8c09
monomer538-809
Assess
JAK2 JH2 in complex with GLPG0634
5ut5
monomer537-808
4×GOL; 1×2HB; 1×ACT; 1×DMS;
Assess
JAK2 JH2 in complex with JAK170
6obb
monomer537-808
1×M3Y;
Assess
JAK2 JH2 in complex with JAK146
6oav
monomer537-808
1×M3A;
Assess
JAK2 JH2 in complex with BI-D1870
5ut1
monomer537-808
4×GOL; 1×7DZ;
Assess
JAK2 JH2 in complex with JAK190
6occ
monomer537-808
1×GOL; 1×M57;
Assess
JAK2 JH2 in complex with XMU-MP-1
6brw
monomer537-808
1×5BS; 1×GOL; 1×ACT;
Assess
JAK2 JH2 in complex with JAK168
6obl
monomer537-808
1×M4P;
Assess
JAK2 JH2 in complex with NU6102
6bss
monomer537-808
1×GOL; 1×4SP;
Assess
JAK2 JH2 in complex with AT9283
5ut0
monomer537-808
2×GOL; 1×35R; 1×ACT; 1×DMS;
Assess
JAK2 JH2 in complex with JNJ-7706621
5usz
monomer537-808
1×SKE; 2×GOL; 1×DMS;
Assess
JAK2 JH2 in complex with JAK064
7jyo
monomer539-808
1×VPS; 1×GOL;
Assess
JAK2 JH2 in complex with JAK067
6xjk
monomer539-807
1×V4D;
Assess

9 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
6e2p.1.Amonomer0.8138-514
100.00
Assess
4oli.1.Amonomer0.71535-1130
46.90
Assess
4fl3.1.Amonomer0.59396-811
1×MG;24.81
Assess
1fmk.1.Amonomer0.58397-811
26.09
Assess
1y57.1.Amonomer0.58397-811
26.09
Assess
1opl.2.Amonomer0.56397-811
25.07
Assess
4xi2.1.Amonomer0.55396-810
24.86
Assess
2j0j.1.Amonomer0.50146-811
23.00
Assess
2j0k.1.Amonomer0.5062-811
21.96
Assess